Larry Anderson, MD, PhD

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Larry Anderson, MD, PhD, discusses recent FDA approvals in multiple myeloma.